Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Stock Has Average Price Target of $23.57 According to Brokerages

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) has earned a consensus recommendation of “Reduce” from the twelve analysts that are currently covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a sell rating and seven have issued a hold rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $23.67.

A number of equities research analysts have recently issued reports on FMS shares. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Sanford C. Bernstein raised their price target on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price target on the stock. in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 4th. Finally, Truist Financial set a $25.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, August 5th.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of NYSE:FMS opened at $22.24 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.02 and a 1 year high of $27.64. The firm has a market capitalization of $11.94 billion, a PE ratio of 11.52, a P/E/G ratio of 4.07 and a beta of 0.74. The business’s 50 day moving average price is $23.33 and its 200-day moving average price is $22.94.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.62 by $0.04. The firm had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%. As a group, equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently made changes to their positions in FMS. Pzena Investment Management LLC lifted its position in Fresenius Medical Care AG & Co. KGaA by 2.0% during the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company’s stock worth $339,592,000 after buying an additional 299,986 shares in the last quarter. Moran Wealth Management LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% in the 1st quarter. Moran Wealth Management LLC now owns 347,773 shares of the company’s stock worth $7,846,000 after acquiring an additional 83,311 shares during the last quarter. Quantinno Capital Management LP increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 15.7% in the 1st quarter. Quantinno Capital Management LP now owns 341,343 shares of the company’s stock worth $7,701,000 after acquiring an additional 46,428 shares during the last quarter. Royal Bank of Canada increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 479.2% in the 1st quarter. Royal Bank of Canada now owns 216,861 shares of the company’s stock worth $4,893,000 after acquiring an additional 179,418 shares during the last quarter. Finally, Assetmark Inc. raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 190.7% during the 1st quarter. Assetmark Inc. now owns 132,320 shares of the company’s stock worth $2,985,000 after acquiring an additional 86,798 shares during the period. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.